Back to School: How biopharma can reboot drug development. Access exclusive analysis here
MedImmune (MEDI) reported second quarter adjusted EPS of $0.06, beating the Street's $0.03
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury